Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5395798 | 0.84 | F10 (0.39) | F10DPP4 | |
| SCHEMBL5375562 | 0.84 | F10 (0.39) | F10DPP4 | |
| SCHEMBL5936046 | 0.80 | F10 (0.58) | F10 | |
| SCHEMBL5936136 | 0.80 | F10 (0.58) | F10 | |
| SCHEMBL5375657 | 0.79 | DPP4 (0.40) | F10DPP4 | |
| SCHEMBL5375589 | 0.79 | DPP4 (0.40) | F10DPP4 | |
| SCHEMBL5720951 | 0.79 | DPP4 (0.40) | F10DPP4 | |
| SCHEMBL5380004 | 0.77 | F10 (0.47) | F10 | |
| SCHEMBL5371113 | 0.77 | F10 (0.47) | F10 | |
| SCHEMBL27613659 | 0.77 | F10 (0.45) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235544-B2 | for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235544-B2 | for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235544-B2 | for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20060178419-A1 | 3-Sulfonylamino-pyrrolindine -2- one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2006-08-10 | — | — | US | disclosed |
| WO-2004110997-A1 | 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178419-A1 | 3-Sulfonylamino-pyrrolindine -2- one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | F10 11/4885DPP4 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.